Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.11
-6.00 (-2.86%)
AAPL  266.22
+1.64 (0.62%)
AMD  195.83
-4.32 (-2.16%)
BAC  51.27
-1.80 (-3.38%)
GOOG  314.02
-0.88 (-0.28%)
META  642.13
-13.53 (-2.06%)
MSFT  385.68
-11.55 (-2.91%)
NVDA  190.87
+1.05 (0.55%)
ORCL  138.78
-9.30 (-6.28%)
TSLA  398.38
-13.44 (-3.26%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.